There are currently 598 clinical trials in Richmond, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Virginia Commonwealth University, Virginia Commonwealth University/Massey Cancer Center, GSK Investigational Site and Virginia Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931
Recruiting
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total occurrences of all-cause mortality (ACM) and cardiovascular (CV) clinical events.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/26/2025
Locations: Research Site, Richmond, Virginia
Conditions: Transthyretin Amyloid Cardiomyopathy
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Bon Secours St. Mary's Hospital, Richmond, Virginia +1 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
NCT05488340
Recruiting
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an activ... Read More
Gender:
FEMALE
Ages:
Between 18 years and 75 years
Trial Updated:
02/24/2025
Locations: Research Site 127, Richmond, Virginia
Conditions: Urinary Tract Infections
Register for Updates
A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors
NCT05653882
Recruiting
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth, Richmond, Virginia
Conditions: Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
Register for Updates
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
NCT06731413
Recruiting
Evaluate frequency of adverse events that lead to chemotherapy discontinuation in vulnerable older adults with recurrent/metastatic PD-L1 TPS\<50% NSCLC patients who receive reduced dose chemotherapy in combination with immunotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Register for Updates
Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
NCT06370000
Recruiting
Test feasibility of an oral maintenance strategy for transplant eligible AML patients in first CR who are medically underserved or have a disadvantage in the CDC SDOH domains
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Acute Myeloid Leukemia
Register for Updates
Anti-Inflammatory Lifestyle Intervention for Emerging Adult Cancer Survivors
NCT06442397
Recruiting
To test the feasibility and acceptability of AILI and associated research procedures among emerging adult cancer survivors (EACS, N=16) age 18-29.
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, School of Medicine, Richmond, Virginia
Conditions: Survivorship
Register for Updates
Health Education Approach to Lung Screening
NCT06070870
Recruiting
Evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (LCS), defined as undergoing a low dose computed tomography (LDCT)
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
02/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Lung Cancer
Register for Updates
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
NCT04643366
Recruiting
This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Virginia Cancer Institute, Richmond, Virginia +1 locations
Conditions: Rectal Cancer
Register for Updates
Immune Registry for BK in Kidney Transplant Recipients
NCT06538961
Recruiting
Kidney transplantation (KT) is the best treatment modality available to date for patients with advanced kidney disease and the success of KT is dependent on maintaining a selective intricate balance between the risk of rejection and infections in KT recipients. BK virus is an important clinical infection affecting the post-transplant outcomes in KT recipients. BK nephropathy can affect 8-15% of patients after KT causing acute kidney injury, increased risk of rejection and fibrosis leading to add... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: BK Virus Infection, Kidney Transplant; Complications
Register for Updates
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
NCT06636123
Recruiting
The purpose of this clinical trial is to determine if GZ17-6.02 delays progression of castration-resistant prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Castration-resistant Prostate Cancer
Register for Updates
A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee
NCT01542580
Recruiting
The purpose of this study is to evaluate performance of the Vanguard 360 revision knee system utilizing offset on either the tibial component, femoral component, or both in terms of the restoration of mechanical alignment, clinical outcomes and survivorship.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: OrthoVirginia West End Orthopedic Clinic, Richmond, Virginia
Conditions: Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity, Complications; Arthroplasty, Deformity of Limb
Register for Updates